Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels

BACKGROUND: Immunotherapy combined with VEGF inhibitor has become the new first-line therapy for advanced or metastatic hepatocellular carcinoma (HCC). However, the biomarkers for response and prognosis stratification of HCC first-line combined immunotherapy have not been clarified. METHODS: Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jiamin, Li, Yinyin, Wang, Xiaohui, Dong, Zheng, Chen, Yan, Zhang, Rui, Huang, Jiagan, Jin, Xueyuan, Yao, Jianfei, Ge, Aifang, Song, Lele, Lu, Yinying, Zeng, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558640/
https://www.ncbi.nlm.nih.gov/pubmed/34737983
http://dx.doi.org/10.2147/JHC.S326356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558640/
https://www.ncbi.nlm.nih.gov/pubmed/34737983
http://dx.doi.org/10.2147/JHC.S326356

Ejemplares similares